EGFR and non-small cell lung carcinoma: In the past decade, non-small cell lung cancer (NSCLC) patients had been proved to have longer progression-free survival (PFS) and better response rate to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) if they a had sensitizing EGFR mutation in phase 3 clinical trials [1,2,3,4,5].